A biomathematical model of human thrombopoiesis under chemotherapy

Journal of Theoretical Biology

Volumn 264, Issue 2, 2010, Pages 287-300

  Scholz, Markus ^a   Gross, Arnd ^a   Loeffler, Markus ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Thrombopheresis; Thrombopoietin; TPO

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; THROMBOPOIETIN; VINCRISTINE;

BIOLOGY; CHEMOTHERAPY; DISEASE TREATMENT; DOSE-RESPONSE RELATIONSHIP; NUMERICAL MODEL; TIME SERIES ANALYSIS; TOXICITY;

ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CELL KINETICS; CELL LOSS; COLONY FORMING UNIT; COMPARTMENT MODEL; CYTOKINE PRODUCTION; HUMAN; MATHEMATICAL MODEL; MEGAKARYOCYTE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SPLEEN FUNCTION; STEM CELL; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; THROMBOCYTOPOIESIS; TREATMENT DURATION; VALIDATION PROCESS;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPUTER SIMULATION; HEMATOPOIETIC STEM CELLS; HUMANS; MODELS, BIOLOGICAL; PLATELET COUNT; THROMBOCYTOPENIA; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 77951652489     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2009.12.032     Document Type: Article

References (74)

1. Begemann H., Rastetter J. Klinische Haematologie 1993, Georg Thieme Verlag Stuttgart, New York.
2. Bender R.A., Castle M.C., Margileth D.A., Oliverio V.T. The pharmacokinetics of [3H]-vincristine in man. Clinical Pharmacology and Therapeutics 1977, 22(4):430-435.
3. Blayney D.W., LeBlanc M.L., Grogan T., Gaynor E.R., Chapman R.A., Spiridonidis C.H., Taylor S.A., Bearman S.I., Miller T.P., Fisher R.I. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and highgrade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). Journal of Clinical Oncology 2003, 21:2466-2473.
4. Blayney D.W., McGuire B.W., Cruickshank S.E., Johnson D.H. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Oncologist 2005, 10:138-149.
5. Broudy V.C., Lin N.L., Sabath D.F., Papayannopoulou T., Kaushansky K. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997, 89(6):1896-1904.
6. Busse D., Busch F.W., Bohnenstengel F., Eichelbaum M., Fischer P., Opalinska J., Schumacher K., Schweizer E., Kroemer H.K. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. Journal of Clinical Oncology 1997, 15(5):1885-1896.
7. Cohen-Solal K., Villeval J.L., Titeux M., Lok S., Vainchenker W., Wendling F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996, 88(7):2578-2584.
8. Corash L. The relationship between megakaryocyte ploidy and platelet volume. Blood Cells 1989, 15:81-107.
9. Crawford J. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. Drugs 2002, 62(Suppl. 1):89-98.
10. Dale D. Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Seminars in Oncology 2003, 30:3-9.
11. Dassin E., Ardaillou N., Eberlin A., Bourebia J., Najean Y. Use of [75Se]-methionine as a tracer of thrombocytopoiesis. II-Kinetics in normal rats and in platelet disorders in man: a new approach. Biochemical and Biophysical Research Communications 1978, 81(2):329-335.
12. Dettke M., Hlousek M., Kurz M., Leitner G., Rosskopf K., Stiegler G., Stohlawetz P., Worel N., Hoecker P., Panzer S. Increase in endogenous thrombopoietin in healthy donors after automated plateletpheresis. Transfusion 1998, 38:449-453.
13. Diehl V., Franklin J., Pfreundschuh M., Lathan B., Paulus U., Hasenclever D., Tesch H., Herrmann R., Dorken B., Muller-Hermelink H.K., Duhmke E., Loeffler M. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine 2003, 348:2386-2395.
14. Ebbe, S., Stohlman, F., Donovan, J., Howard, D.,1966. Megakaryocytopoiesis in the rat with transfusion-induced thrombocytosis. Proceedings of the Society for Experimental Biology and Medicine 122 (4), 1053-1057.
15. Ebbe S., Stohlman F., Donovan J., Overcash J. Megakaryocyte maturation rate in thrombocytopenic rats. Blood 1968, 32(5):787-795.
16. Ebbe S., Yee T., Carpenter D., Phalen E. Megakaryocytes increase in size within ploidy groups in response to the stimulus of thrombocytopenia. Experimental Hematology 1988, 16:55-61.
17. Emmons R.V.B., Reid D.M., Cohen R.L., Meng G., Young N.S., Dunbar C.E., Shulman N.R. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996, 87(10):4068-4071.
18. Engel C., Loeffler M., Franke H., Schmitz S. Endogenous thrombopoietin serum levels during multicycle chemotherapy. British Journal of Haematology 1999, 105:832-838.
19. Engel C., Scholz M., Loeffler M. A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. Blood 2004, 104(8):2323-2331.
20. Fielder P.J., Gurney A.L., Stefanich E., Marian M., Moore M.W., Carver-Moore K., de Sauvage F.J. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996, 87(6):2154-2161.
21. Finch C.A., Harker L.A., Cook J.D. Kinetics of the formed elements of human blood. Blood 1977, 50(4):699-707.
22. Freedman M.L., Karpatkin S. Heterogeneity of rabbit platelets. V. Preferential splenic sequestration of megathrombocytes. British Journal of Haematology 1975, 31:255-262.
23. Freedman M., Altszuler N., Karpatkin S. Presence of a nonsplenic platelet pool. Blood 1977, 50(3):419-425.
24. Geddis A.E. The regulation of proplatelet production. Haematologica 2009, 94(6):756-759.
25. Gehrmann G., Elbers C., Berninger F.S. Pooling and destruction of platelets in the spleen in hypersplenism. Klinische Wochenschrift 1972, 50:379-382.
26. Glauche I., Cross M., Loeffler M., Roeder I. Lineage specification of hematopoietic stem cells: mathematical modeling and biological implications. Stem Cells 2007, 25(7):1791-1799.
27. Harker L.A. Platelet production and its regulation. Platelet Kinetics 1971, 202-211. North-Holland Publishing Company. J.M. Paulus (Ed.).
28. Harker L.A., Roskos L.K., Marzec U.M., Carter R.A., Cherry J.K., Sundell B., Cheung E.N., Terry D., Sheridan W. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000, 95:2514-2522.
29. Horie K., Miyazaki H., Hagiwara T., Tahara E., Matsumoto A., Kadoya T., Ogami K., Kato T. Action of thrombopoietin at the megakaryocyte progenitor level is critical for the subsequent proplatelet production. Experimental Hematology 1997, 25(2):169-176.
30. Hortobagyi G.N. Progress in systemic chemotherapy of primary breast cancer: an overview. Journal of the National Cancer Institute. Monographs 2001, 30:72-79.
31. Jin F., Krzyzanski W. Pharmacokinetic model of target-mediated disposition of thrombopoietin. The AAPS Journal 2004, 6(1):86-93.
32. Karpatkin S. Human platelet senescence. Annual Review of Medicine 1972, 23:101-128.
33. Kaushansky K., Lin N., Grossmann A., Humes J., Sprugel K.H., Broudy V.C. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Experimental Hematology 1996, 24(2):265-269.
34. Kaushansky K. Thrombopoietin: more than a lineage-specific megakaryocyte growth factor. Stem Cells 1997, 15(Suppl. 1):97-102.
35. Kaushansky K., Lok S., Holly R.D., Broudy V.C., Lin N., Bailey M.C., Forstrom J.W., Buddle M.M., Oort P.J., Hagen F.S., Roth G.J., Papayannopoulou T., Foster D.C. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 2004, 369:568-571.
36. Kliem, C., 2001. Entwicklung eines mathematischen Kompartmentmodells zur Regulation der murinen Thrombopoese auf der Basis von Stoerungsmustern der thrombopoetischen Zellreihe. Dissertation, Universitaet Leipzig.
37. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
38. Kuter, D.J., Beeler, D.L., Rosenberg, R.D., 1994. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proceedings of the National Academy of Science USA 91(23), 11104-11108.
39. Kuter D.J., Begley C.G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002, 100(10):3457-3469.
40. Li J., Xia Y., Kuter D.J. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. British Journal of Haematology 1999, 106(2):345-356.
41. Lohrmann H.P., Schreml W. Cytotoxic Drugs and the Granulopoietic System 1982, Springer, Berlin.
42. McCarty J.M., Sprugel K.H., Fox N.E., Sabath D.E., Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995, 86(10):3668-3675.
43. von Minckwitz G., Raab G., Caputo A., Schutte M., Hilfrich J., Blohmer J.U., Gerber B., Costa S.D., Merkle E., Eidtmann H., Lampe D., Jackisch C., du Bois A., Kaufmann M. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. Journal of Clinical Oncology 2005, 23:2676-2685.
44. Miyazaki M., Fujiwara Y., Isobe T., Yamakido M., Kato T., Miyazaki H. The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer. Anticancer Research 1999, 19:667-670.
45. Mukai H.Y., Kojima H., Todokoro K., Tahara T., Kato T., Hasegawa Y., Kobayashi T., Ninomiya H., Nagasawa T., Abe T. Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thrombosis and Haemostasis 1996, 76(5):675-678.
46. Nichol J.L., Hokom M.M., Hornkohl A., Sheridan W.P., Ohashi H., Kato T., Li Y.S., Bartley T.D., Choi E., Bogenberger J., Skrine J.D., Knudten A., Chen J., Trail G., Sleeman L., Cole S., Grampp G., Hunt P. Megakaryocyte growth and development factor-analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. Journal of Clinical Investigation 1995, 95:2973-2978.
47. Obeyesekere M.N., Berry R.W., Spicer P.P., Korbling M. A mathematical model of haematopoiesis as exemplified by CD34 cell mobilization into the peripheral blood. Cell Proliferation 2004, 37:279-294.
48. Pfreundschuh M., Trumper L., Kloess M., Schmits R., Feller A.C., Rube C., Rudolph C., Reiser M., Hossfeld D.K., Eimermacher H., Hasenclever D., Schmitz N., Loeffler M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
49. Pfreundschuh M., Trumper L., Kloess M., Schmits R., Feller A.C., Rudolph C., Reiser M., Hossfeld D.K., Metzner B., Hasenclever D., Schmitz N., Glass B., Rube C., Loeffler M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004, 104:626-633.
50. Pfreundschuh, M., Zwick, C., Zeynalova, S., Duehrsen, U., Pflueger, K.H., Vrieling, T., Mesters, R., Mergenthaler, H.G., Einsele, H., Bentz, M., Lengfelder, E., Truemper, L., Ruebe, C., Schmitz, N., Loeffler, M., German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) (2008). Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of Oncology 19 (3), 545-552.
51. Santillan M., Mahaffy J.M., Belair J., Mackey M.C. Regulation of platelet production: the normal response to perturbation and cyclical platelet disease. Journal of Theoretical Biology 2000, 206(4):585-603.
52. de Sauvage F.J., Hass P.E., Spencer S.D., Malloy B.E., Gurney A.L., Spencer S.A., Darbonne W.C., Henzel W.J., Wong S.C., Kuang W.J., Oles K.J., Hultgren B., Solberg L.A., Goeddel D.V., Eaton D.L. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994, 369(6481):533-538.
53. Schmitt A., Guichard J., Masse J.M., Debili N., Cramer E.M. Of mice and men: comparison of the ultrastructure of megakaryocytes and platelets. Experimental Hematology 2001, 29:1295-1302.
54. Scholz M., Engel C., Loeffler M. Modelling human granulopoiesis under polychemotheraphy with G-CSF support. Journal of Mathematical Biology 2005, 50(4):397-493.
55. Scholz M., Engel C., Loeffler M. Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia. British Journal of Haematology 2006, 132:723-735.
56. Scholz, M., Engel, C., Apt, D., Sankar, S.L., Goldstein, E., Loeffler, M., 2009. Pharmacokinetic and Pharmacodynamic modelling of the novel human G-CSF derivative Maxy-G34 and Pegfilgrastim in the rat. Cell Proliferation, in press.
57. Schuster M.W., Beveridge R., Frei-Lahr D., Abboud C.N., Cruickshank S., Macri M., Menchaca D., Holden J., Waller E.K. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Experimental Hematology 2002, 30:1044-1050.
58. Schwefel H.P. Evolution strategies: a family of nonlinear optimization techniques based on imitating some principles of organic evolution. Annals of Operations Research 1984, 1:65-167.
59. Schwenkglenks M., Jackisch C., Constenla M., Kerger J.N., Paridaens R., Auerbach L., Bosly A., Pettengell R., Szucs T.D., Leonard R. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 2006, 14:901-909.
60. Selivanov V.A., Lanin V.N. Mathematical model study of megakaryocytopoiesis. 1. The simulation model, cell steady-state distribution and the number of divisions in a proliferating population. Ontogenez 1986, 17:270-277.
61. Shipp M.A., Neuberg D., Janicek M., Canellos G.P., Shulman L.N. High-dose CHOP as initial therapy for patients with poor prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. Journal of Clinical Oncology 1995, 13:2916-2923.
62. Siena S., Secondino S., Giannetta L., Carminati O., Pedrazzoli P. Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy. Critical Reviews in Oncology/Hematology 2003, 48:S39-S47.
63. Sinkule J.A. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy 1984, 4(2):61-73.
64. Skomorovski K., Harpak H., Ianovski A., Vardi M., Visser T.P., Hartong S.C.C., van Vliet H.H.D.M., Wagemaker G., Agur Z. New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model. British Journal of Haematology 2003, 123:683-691.
65. Stefanich E., Senn T., Widmer R., Fratino C., Keller G.A., Fielder P.J. Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice. Blood 1997, 89(11):4063-4070.
66. Stenberg P.E., Levin J. Mechanisms of platelet production. Blood Cells 1989, 15:23-47.
67. Tsan M.F. Kinetics and distribution of platelets in man. American Journal of Hematology 1984, 17(1):97-104.
68. Vadhan-Raj S., Murray L.J., Bueso-Ramos C., Patel S., Reddy S.P., Hoots W.K., Johnston T., Papadopolous N.E., Hittelman W.N., Johnston D.A., Yang T.A., Paton V.E., Cohen R.L., Hellmann S.D., Benjamin R.S., Broxmeyer H.E. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Annals of Internal Medicine 1997, 126(9):673-681.
69. Wagner T., Schwartz D.W.M., Winter M., Kabrna E., Kollars M., Schwarzinger I., Lanzer G., Mayr W.R., Geissler K. Kinetics of CFU-Mk after automated plateletpheresis. Vox Sanguinis 2001, 81:167-171.
70. Weisbach V., Friedlein H., Glaser A., Zingsem J., Zimmermann R., Eckstein R. The influence of automated plateletpheresis on systemic levels of hematopoietic growth factors. Transfusion 1999, 39:889-894.
71. Wichmann H.E. Regulationsmodelle und ihre Anwendung auf die Blutbildung - Band 48 der Reihe Medizinische Informatik und Statistik 1984, Springer, Berlin, Heidelberg.
72. Wichmann H.E., Loeffler M. Mathematical Modeling of Cell Proliferation: Stem Cell Regulation in Hemopoiesis 1985, CRC Press, Boca Raton.
73. Wunderlich A., Kloess M., Reiser M., Rudolph C., Truemper L., Bittner S., Schmalenberg H., Schmits R., Pfreundschuh M., Loeffler M. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of Oncology 2003, 14:881-893.
74. Ziepert M., Schmits R., Truemper L., Pfreundschuh M., Loeffler M. Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. Annals of Oncology 2008, 19(4):752-762.